Canada - English - Health Canada
250 and 500 mg Capsules
125 mg/5 mL Powder for Oral Solution
DATE OF PREPARATION:
150 Signet Drive
July 26, 2000
DATE OF REVISION:
May 16, 2019
Control No.: 221440
1) 4-Thia-1-azabicyclol[3.2.0]heptane-2-carboxylic acid, 6-[[[3-
dimethyl-7- oxo-, monosodium salt, monohydrate, [2S-
2) Monosodium (2S, 5R, 6R)-6-[3-(o-chlorophenyl)-5-
1-azabicyclo [3.2.0]heptane-2-carboxylate monohydrate
Cloxacillin sodium is a white, odorless, crystalline powder. It is
freely soluble in water, soluble in alcohol and slightly soluble in
In addition to cloxacillin sodium, APO-CLOXI capsules also contain the non-medicinal
ingredients colloidal silicon dioxide, stearic acid, and talc (as an antistatic agent). The capsule
shells, imprinted with edible white ink, contain the non-medicinal ingredients D&C yellow #10,
FD&C blue #1, FD&C red #40, FD&C yellow #6, gelatin, silicon dioxide, sodium lauryl sulfate
and titanium dioxide.
In addition to cloxacillin sodium, APO-CLOXI powder for oral solution also contains the non-
medicinal ingredients FD&C red #40, sodium benzoate, sodium citrate (anhydrous), sodium
cyclamate, sucrose, and artificial cherry flavour.
250 mg and 500 mg Capsules
125 mg/5 mL Powder for Oral Solution
Cloxacillin sodium is an antibiotic belonging to the semi-synthetic penicillin family.
APO-CLOXI exhibits a bacterial action against sensitive organisms during the active
multiplication stage. It acts through the inhibition of biosynthesis of cell wall mucopeptides.
INDICATIONS AND CLINICAL USE
APO-CLOXI (cloxacillin sodium) finds use in the treatment of infections caused by streptococci
when associated with sensitive penicillinase-producing staphylococci; also in the treatment of
all staphylococcal infections, whether penicillin G-sensitive or resistant.
In infections suspected of being caused by penicillinase-producing staphylococci, cloxacillin
may be used for initial treatment after appropriate specimens have been taken for culture and
before results of microbial susceptibility tests are known. If the results of identification and
susceptibility tests indicate that the infecting organism is not a penicillinase-producing
staphylococcus susceptible to cloxacillin, cloxacillin should be discontinued and treatment with
an appropriate alternative agent instituted.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO-
CLOXI and other antibacterial drugs, APO-CLOXI should be used only to treat infections that
are proven or strongly suspected to be caused by susceptible bacteria. When culture and
susceptibility information are available, they should be considered in selecting or modifying
antibacterial therapy. In the absence of such data, local epidemiology and susceptibility
patterns may contribute to the empiric selection of therapy.
A history of allergic reactions to penicillin or cephalosporins.
Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in
patients receiving penicillin therapy. These reactions are more apt to occur in individuals with a
history of sensitivity to multiple allergens. Careful inquiry should be made concerning previous
hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic or
anaphylactic reaction occurs, discontinue treatment and administer the usual agents, e.g.
antihistamines, pressor amines, corticosteroids.
Safety for use in pregnancy has not been established.
Development of Drug Resistant Bacteria
Prescribing APO-CLOXI in the absence of a proven or strongly suspected bacterial infection
is unlikely to provide benefit to the patient and risks the development of drug-resistant
Candidiasis and other superinfections may occur, especially in debilitated and malnourished
patients, or those with low resistance to infection due to corticosteroids, immunosuppressive
agents or irradiation. If superinfection occurs, institute appropriate measures.
During long-term therapy, renal, hepatic and hematopoietic functions should be checked
Experience in premature and newborn infants is limited. Cautious administration of the drug
to such patients and frequent evaluation of organ system function is recommended.
The passage of any penicillin from blood into brain is facilitated by inflamed meninges and
during cardiopulmonary bypass. In the presence of such factors, particularly in renal failure
when high serum concentrations can be attained, central nervous system adverse effects
including myoclonia, convulsive seizures and depressed consciousness can be expected.
Although this complication has not been reported with cloxacillin, it should be anticipated.
Gastrointestinal disturbances, such as nausea, vomiting, epigastric discomfort, flatulence and
loose stools, have been noted in some patients. Rarely, mild leukopenia has occurred. Mildly
elevated SGOT levels (less than 100 units) have been reported in a few patients for whom
pre-therapeutic determinations were not made. Fever, anaphylaxis and allergic reactions
(rash, urticaria) including wheezing and sneezing, have occasionally been encountered.
Eosoinophilia, with or without overt allergic manifestations, has been noted in some patients
during therapy. Thrombophlebitis has occurred occasionally I.V. therapy.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
When penicillin reaches a certain (as yet undetermined) concentration in the cerebrospinal fluid,
neurotoxic symptoms may occur consisting of myoclonia, convulsive seizures, and depressed
consciousness. Unless administration of the drug is stopped or its dosage reduced, the
syndrome may progress to coma and death. Penicillin does not normally cross the blood-brain
barrier to any substantial extent, but when massive doses are used (several grams a day) in the
presence of inflamed meninges and/or impaired renal function, or in elderly patients, the drug
may cause the above- mentioned toxic reactions. No antidote is required.
Treatment of overdose:
Stop administration temporarily - promote excretion (dialysis, etc.).
Toxic serum levels and the lethal serum level of cloxacillin in man are not known.
APO-CLOXI (cloxacillin sodium) is bactericidal and has an anti- bacterial spectrum similar to
that of benzylpenicillin but is less active. It is also effective in the dosage recommended for
treatment of infections caused by streptococci and penicillin-G sensitive staphylococci.
The average minimal inhibitory concentrations (M.I.C.) of sodium cloxacillin monohydrate for
these organisms are as follows:
1, 2, 3, 4, 5
Sodium cloxacillin monohydrate is rapidly but incompletely absorbed from the gastrointestinal
tract after oral administration.
When a dose of 500 mg cloxacillin sodium (2 x 250 mg cloxacillin sodium capsules) was
administered to fasting adult volunteers a mean peak plasma level of 8.5 mcg/mL was obtained
with a T
of 0.88 hr.
A dose of 500 mg cloxacillin sodium reconstituted granules for oral solution yielded peak plasma
levels of 13.3 mcg/mL with a T
of 0.58 hr. in fasting adult volunteers.
Oral doses of 250 mg sodium cloxacillin to adult fasting volunteers resulted in 4.8 mcg/mL peak
serum levels with a T
of 1 hr.
Mean urinary excretion of cloxacillin after an oral dose of 500 mg was found to be 37%.
urinary excretion in healthy volunteers was 62% of an intravenously injected dose of 750 mg
(250 mg/hr for three hours).
Food delays the absorption of cloxacillin sodium. cloxacillin.
Sodium cloxacillin is bound to
serum proteins to the extent of 94%.
The plasma half-life of cloxacillin is reported to be 25 minutes in healthy volunteers following
infusion of 750 mg over a 3 hour period.
The plasma half-life in uremic patients was increased
to 49 minutes.
Cloxacillin passage across the CNS barrier is insufficient for practical purposes unless the
meninges are inflamed. Cloxacillin passes the placental barrier as do the penicillins to the extent
of about 50% of the mothers plasma level.
Serum concentrations are enhanced if probenecid is given concomitantly.
Cloxacillin sodium shares the lack of toxicity of other penicillins. It has been administered to
mice, rats, dogs, cats and rabbits by various routes.
Studies on the acute toxicity of cloxacillin sodium have shown that it has a very low acute
toxicity whether given orally or parenterally. Studies on newborn rats also show low toxicity.
The oral LD
in mice was more than 5,000 mg/kg and 1,200 mg/kg by intravenous injection.
Cloxacillin sodium in doses of 100 mg and 500 mg/kg was administered orally and
subcutaneously to two groups of 12 male rats each over a period of 12 weeks. No
haematological, biochemical, histological or organ weight abnormalities were observed.
Sodium cloxacillin was administered in doses of 500 mg and 2000 mg/kg twice daily to two
groups of 3 dogs each for a period of 4 weeks. No haematological, biochemical or histological
abnormalities were noted.
No evidence of teratogenicity was reported in a study of sodium cloxacillin given intramuscularly
to female rabbits.
Six pregnant rabbits were administered 250 mg/kg cloxacillin from the 8th
day to the 16th of pregnancy. The animals given cloxacillin had no abortions and delivered
normal sized litters with no fetal abnormalities.
DOSAGE AND ADMINISTRATION
Mild to moderate infections: 250 to 500 mg every 6 hours. It should be given l to 2
hours before meals as the presence of food in the stomach and small intestine
reduces absorption. Maintain therapy for a minimum of 5 days.
Larger doses may be required for very severe infections.
A daily dose of 6 g should not be exceeded.
Up to 5 kg (11 lb) body weight: 250 mg/day.
Over 5 kg (11 lb) up to approximately 40 kg (85 lb) body weight: 50 mg/kg/day.
Total daily dosage must be divided into 4 doses, 1 dose given every 6 hours.
In infections associated with streptococcus pyogenes, treatment should be continued for at least
10 days to reduce the risk of glomerulonephritis or rheumatic fever.
AVAILABILITY OF DOSAGE FORMS
250 mg: Each orange and black no. 2 capsule, identified APO 250, contains cloxacillin sodium
equivalent to cloxacillin 250 mg. Available in bottles of 100 and 1000 capsules.
500 mg: Each orange and black no. 0 capsule, identified APO 500, contains cloxacillin sodium
equivalent to cloxacillin 500 mg. Available in bottles of 100 and 500.
Powder For Oral Solution
After reconstitution, each 5 mL of pink, cherry flavoured solution contains cloxacillin
sodium equivalent to 125 mg cloxacillin. Available in 60 mL, 100 mL and 200 mL
STORAGE AND STABILITY
Stability and Storage Recommendations
Store at room temperature not exceeding 25°C.
APO-CLOXI powder for oral solution is reconstituted with water as follows:
60 mL: Reconstitute by adding 42 mL of water to make 60 mL.
100 mL: Reconstitute by adding 70 mL to make 100 mL.
200 mL: Reconstitute by adding 140 mL to make 200 mL.
The reconstituted solution is stable for 14 days under refrigeration.
Knudsen, E.T., Brown, D.M., Rolinson, G.N.: A New Orally Effective Penicillinase-Stable
Penicillin - BRL. 1621. The Lancet, ii:632, 1962.
Smith, J.T., Hamilton-Miller, J.M.T., Knox, R.: Isoxazolyl Penicillins and Penicillinase.
Nature, 195:1300, 1962.
Nayler, J.H.C., Long, A.A.W., Brown, D.M., Acred, P., Rolinson, G.N., Batchelor, F.R.,
Stevens, S., Sutherland, R.: Chemistry, Toxicology, Pharmacology and Microbiology of a
New Acid-Stable Penicillin, Resistant to Penicillinase (BRL 1621). Nature, 195:1264,
Bunn, P.A., Milicich, S.: Laboratory and Clinical Studies with Cloxacillin. Antimicrobial
Agents and Chemotherapy, 220,1963.
Cravenkemper, C.F., Bennett, J.V., Brodie, J.L., and Kirby, W.M.M.: Dicloxacillin:In Vitro
and Pharmacologic Comparison with Oxacillin and Cloxacillin. Arch. Intern. Med.,
"A Comparative Bioavailability Study of 250 mg Cloxacillin Capsules''.Report 27205,
Sept. 1975, Teva Canada Limited.
A Comparative Bioavailability Study of Cloxacillin for Oral Solution". Report 30067, Jan.
1976, Teva Canada Limited.
Bodey, G.P., Vellejos, C., and Stewart, D.: Flucloxacillin: A New Semisynthetic
Isoxazolyl Penicillin.Clin. Pharm. Ther.13:512, 1972.
Sidell, S., Bulger, R.J., Brodie, J.L., Kirby, W.M.M.: Cloxacillin a New Oral Synthetic
Penicillin (Comparisons with Oxacillin). Clin. Pharm. Ther., 5:26, 1964.
Kislak, J.W., Eickhoff, T., Finland, M.: Cloxacillin: Activity In Vitro, and Absorption and
Excretion in Normal Young Men. Am. J. Med. Sciences, 249:750, 1965.
Rolinson, G.N., and Sutherland, R.: The Binding of Antibiotics to Serum Proteins. Brit. J.
Pharmacal. 25 :638, 1965.
Rosenblatt, J.E., Kind, A.C., Brodie, J.L., and Kirby, W.M.M.: Mechanisms Responsible
for the Blood Level Differences of Isoxazolyl Penicillins. Arch. Intern. Med., 121:345,
Acred, P., and Brown, D.M.: Further Pharmacology and Chemotherapy of Cloxacillin.
Brit. J. Pharmacol. 21:339, 1963.
Rutenburg, A.M., Greenberg, H.L., Levenson, S.S., Schweinburg, F.B.: Clinical
Evaluation of 5-Methyl-3-Phenyl-4-Isoxazolyl Penicillin in Staphylococcal Infections. New
Engl. J. Med.,266:755, 1962.
Stewart, G.T., ed. et al.:Clinical and Laboratory Results with BRL 1621: A Report from
Six Hospitals. The Lancet ii:634,1962.
Stratford, B.C.: Clinical and Laboratory Experiences with Cloxacillin. Med. J. Australia
Klein, J.O., Finland, M.: The New Penicillins. New Eng. J. Med. 269:1019, 1963.
Boger, W.P., Gavin, J.J.: Comparison of Cloxacillin, Oxacillin and Phenoxymethyl
Penicillin. Chemotherapia 8:142, 1964.
Kunin, C.M.: Clinical Pharmacology of New Penicillins. Clin. Pharmacol. Ther., 7:166,
Idsoe, O., Guthe, T., Willcox, R.R., and De Week, A.L.: Nature and Extent of Penicillin
Side-Reactions, with Particular Reference to Fatalities from Anaphylactic Shock. Bulletin
World Health Organization, 38:159, 1968.
Howell, A., Sutherland, R., and Rolinson, C.N.: Penetration of Ampicillin and Cloxacillin
into Synovial Fluid and the Significance of Protein Binding on Drug Distribution. Annals
Rheumatic Disease, 31:538, 1972.
Ferrieri, P., Dajani, A.S., and Wannamaker, L.W.: A Controlled Study of Penicillin
Prophylaxis Against Streptococcal Impetigo. J. Infect. Dis., 129:429, 1974.
Strominger, J.L.: The Action of Penicillin and Other Antibiotics on Bacterial Wall
Synthesis. Johns Hopkins Med. J., 133:63, 1973.
McCracken, G.H. Jr., Ginsberg, C., Chrane, D.F., Thomas, M.A., and Horton, L.J.:
Clinical Pharmacology of Penicillin in New- born Infants. J. Pediat., 82:692, 1973.
Cloxacillin Sodium Monograph, Martindale: The Extra Pharmacopoeia 27th ed., 1118-
1120, 1977, Pharmaceutical Society Great Britain, London.
Weinstein, L.: Chapter 57 "Penicillins and Cephalosporins" p. 1130 in The
Pharmacological Basis of Therapeutics, 5th ed., L.S. Goodman, A. Gilman, ed., Collier
MacMillan, Toronto, 1975.
Product Monograph “
TEVA-CLOXACILLIN” (cloxacillin sodium); 250 mg and 500 mg
Capsules and 125 mg/5 mL Granules for Oral Solution; Teva Canada Limited; Date of
revision: June 21, 2018; Control No.: 211320.
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION
250 and 500 mg Capsules
125 mg/5 mL Powder for Oral Solution
Read this carefully before you start taking APO-CLOXI and each time you get a refill. This
leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare
professional about your medical condition and treatment and ask if there is any new information
What is APO-CLOXI used for?
APO-CLOXI is used to treat infections that are caused by certain bacteria.
Antibacterial drugs like APO-CLOXI treat only bacterial infections. They do not treat viral
How does APO-CLOXI work?
APO-CLOXI is an antibiotic that works by:
Stopping the growth of bacteria.
What are the ingredients in APO-CLOXI?
Capsule: Colloidal silicon dioxide, stearic acid, and talc (as an antistatic agent). The capsule
shell, imprinted with edible white ink, contain D&C yellow #10, FD&C blue #1, FD&C red #40,
FD&C yellow #6, gelatin, silicon dioxide, sodium lauryl sulfate and titanium dioxide.
Powder for Oral Suspension: FD&C red #40, sodium benzoate, sodium citrate (anhydrous),
sodium cyclamate, sucrose, and artificial cherry flavour.
APO-CLOXI comes in the following dosage forms:
Capsules: 250 mg and 500 mg
Suspension: 125 mg / 5 mL
Do not use APO-CLOXI if:
You have had an allergic reaction to APO-CLOXI or other medicines such as
cephalosporins or penicillins.
To help avoid side effects and ensure proper use, talk to your healthcare professional
before you take APO-CLOXI. Talk about any health conditions or problems you may
have, including if you:
Have severe kidney disease with or without significant liver disease
Are pregnant or could become pregnant during treatment
Are breast feeding
How to take APO-CLOXI:
Take APO-CLOXI 1-2 hours before eating.
Although you may feel better early in treatment, APO-CLOXI should be used exactly as
Misuse or overuse of APO-CLOXI could lead to the growth of bacteria that will not be
killed by APO-CLOXI (resistance). This means that APO-CLOXI may not work for you in
Do not share your medicine.
Adults: 250 mg to 500 mg every 6 hours. Do not take more than 6000 mg daily.
Children weighing less than 5 kg (11 lbs): 250 mg per day.
Children weighing more than 5 kg (11 lbs): 50 mg / kg / day.
If you think you have taken too much APO-CLOXI, contact your healthcare professional,
hospital emergency department or regional poison control centre immediately, even if there
are no symptoms.
What are possible side effects from using APO-CLOXI?
These are not all the possible side effects you may feel when taking APO-CLOXI. If you
experience any side effects not listed here, contact your healthcare professional.
Upper stomach pain
Other side effects may occur that usually do not need medical attention. These side effects may
go away during treatment as your body adjusts to the medicine. However, check with your
doctor for any side effect that seems unusual or that is especially bothersome.
Serious side effects and what to do about them:
Symptom / effect
Talk to your
drug and get
an allergic reaction (difficulty in breathing,
closing of the throat, swelling of the lips, face
or tongue; hives or a rash)
redness, or itching
severe nausea, vomiting, or diarrhea
This is not a complete list of side effects. For any unexpected effects while taking APO-CLOXI,
contact your doctor or pharmacist.
Reporting Side Effects
You can report any suspected side effects associated with the use of health products to Health
Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-
for information on how to report online, by mail or by fax; or
Calling toll-free at 1-866-234-2345.
NOTE: Contact your health professional if you need information about how to manage your side
effects. The Canada Vigilance Program does not provide medical advice.
How to store APO-CLOXI:
Capsules: Store at room temperature not exceeding 25°C.
Powder for Oral Solution: The reconstituted solution is stable for 14 days under refrigeration.
Keep out of reach and sight of children.
If you want more information about APO-CLOXI:
Talk to your healthcare professional
Find the full product monograph that is prepared for healthcare professionals and includes
this Patient Medication Information by visiting the Health Canada website (http://hc-
sc.gc.ca/index-eng.php); the manufacturer's website http://www.apotex.ca/products, or by
This leaflet was prepared by Apotex Inc., Toronto, Ontario, M9L 1T9.
Last revised: May 16, 2019